To assess if the drugs maintain neuroprotective potency in a human model, we used the human neuroglioma cell line (H4) transfected with wild-type and A4V SOD1 and assessed the cell viability using MTS assay following treatment with ebselen, MR6-8-2 and MR6-26-2 along with two approved ALS drugs—riluzole and edaravone (Fig. 1C). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.